Aclaris Therapeutics Inc. (ACRS) Financial Statements (2024 and earlier)

Company Profile

Business Address 701 LEE ROAD
WAYNE, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:229,800225,70054,10075,015167,972208,854
Cash and cash equivalents45,27727,34922,063  20,202
Short-term investments172,294164,06532,06839,078110,953173,655
Other undisclosed cash, cash equivalents, and short-term investments12,22934,286(31)35,93757,01914,997
Receivables4846237727044,861481
Inventory, net of allowances, customer advances and progress billings     791 
Inventory     791 
Disposal group, including discontinued operation    4,966  
Other undisclosed current assets1,266(21,291)2,6213,1185,875(9,114)
Total current assets:231,550205,03257,49383,803179,499200,221
Noncurrent Assets
Property, plant and equipment1,0991,3351,6542,4704,2802,159
Long-term investments and receivables12,24234,242   14,997
Long-term investments12,24234,242   14,997
Intangible assets, net (including goodwill)6,9737,0487,1237,19991,45525,853
Goodwill     18,50418,504
Intangible assets, net (excluding goodwill)6,9737,0487,1237,19972,9517,349
Other noncurrent assets2,7323,5544,5144,825332279
Total noncurrent assets:23,04646,17913,29114,49496,06743,288
TOTAL ASSETS:254,596251,21170,78498,297275,566243,509
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities19,05220,03611,16017,63827,34212,762
Accounts payable10,3519,9855,2549,91714,7557,822
Accrued liabilities8,70110,0515,9067,72112,5874,940
Disposal group, including discontinued operation2,2022,2023,1114,157  
Other liabilities  693603637  
Other undisclosed current liabilities684     
Total current liabilities:21,93822,93114,87422,43227,34212,762
Noncurrent Liabilities
Long-term debt and lease obligation:   2,894   
Liabilities, other than long-term debt35,03730,9397,6075,9533,1865,485
Deferred tax liabilities, net549549
Deferred income tax liabilities 367367367549
Other liabilities1,5702,1723,1793,7361,703558
Operating lease, liability   2,894 
Business combination, contingent consideration, liability33,10028,4004,0611,6689344,378
Other undisclosed noncurrent liabilities   7,759 29,914 
Total noncurrent liabilities:35,03730,93918,2605,95333,1005,485
Total liabilities:56,97553,87033,13428,38560,44218,247
Equity
Equity, attributable to parent197,621197,34137,65069,912215,124225,262
Common stock11    
Additional paid in capital880,832792,971542,286523,505507,366384,943
Accumulated other comprehensive loss(897)(224)(94)(66)(69)(246)
Accumulated deficit(682,315)(595,407)(504,542)(453,527)(292,173)(159,435)
Total equity:197,621197,34137,65069,912215,124225,262
TOTAL LIABILITIES AND EQUITY:254,596251,21170,78498,297275,566243,509

Income Statement (P&L) ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues29,7526,7616,4824,22710,0911,683
Revenue, net1,683
Cost of revenue(4,023)(4,713)(5,133)(4,055)(6,850)(1,207)
Gross profit:25,7292,0481,3491723,241476
Operating expenses(102,946)(67,432)(52,261)(111,230)(138,655)(72,899)
Other undisclosed operating income (loss)(12,637)(24,339)    
Operating loss:(89,854)(89,723)(50,912)(111,058)(135,414)(72,423)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
2,946(1,142)(424)(2,484)2,6762,070
Interest and debt expense  (752)(5)(87)  
Other undisclosed income from continuing operations before equity method investments, income taxes   144   
Loss from continuing operations before equity method investments, income taxes:(86,908)(91,617)(51,197)(113,629)(132,738)(70,353)
Other undisclosed income (loss) from continuing operations before income taxes  752(139)(47,725)  
Loss from continuing operations before income taxes:(86,908)(90,865)(51,336)(161,354)(132,738)(70,353)
Income tax benefit  182  1,830
Loss from continuing operations:(86,908)(90,865)(51,154)(161,354)(132,738)(68,523)
Loss before gain (loss) on sale of properties:(90,865)(51,015)(161,354)(132,738)(68,523)
Income from discontinued operations   139   
Net loss available to common stockholders, diluted:(86,908)(90,865)(51,015)(161,354)(132,738)(68,523)

Comprehensive Income ($ in thousands)

12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(86,908)(90,865)(51,015)(161,354)(132,738)(68,523)
Other comprehensive income (loss)(673)(130)(28)317723
Comprehensive loss, net of tax, attributable to parent:(87,581)(90,995)(51,043)(161,351)(132,561)(68,500)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: